Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

RARE stock hub

Ultragenyx Pharmaceutical Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RAREis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.6B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

RARE

In the news

Latest news · RARE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-33

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RARE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

206

Groups with data

Currency

USD

Showing 206 of 206 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001515673
Company name	Ultragenyx Pharmaceutical Inc.
Country	United States
Country code	US
Cusip	90400D108
Employees	1,371
Employees Change	77%
Employees Change Percent	5.95
Enterprise value	$3.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2014-01-31
Isin	US90400D1081
Last refreshed	2026-05-10
Market cap	$2.6B
Market cap category	Mid-Cap
Price	$26.12
Price currency	USD
Rev Per Employee	488,694.38x
Sector	Healthcare
Sic	2834
Symbol	RARE
Website	https://www.ultragenyx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-23.75%
EV Sales Forward	4.04x
EV/Sales	4.82x
FCF yield	-19.61%
P/S ratio	3.83x
PS Forward	3.21x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-79.25%
EBITDA Margin	-74.18%
Gross margin	-28.06%
Gross Profit	$-188M
Net Income	$-609M
Net Income Growth Years	0%
Pretax Margin	-90.3%
Profit Margin	-90.9%
Profit Per Employee	$-444,201
ROA	-25.45
Roa5y	-21.76
ROCE	-54.69
Roe5y	-233.6
ROIC	-32.99

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-8.45%
Cagr1y	-21.86%
Cagr3y	-17.91%
Cagr5y	-25.6%
EPS Growth Years	3
Revenue Growth	13.53x
Revenue Growth Q	-2.16x
Revenue Growth Years	9x
Revenue Growth3 Y	20.4x
Revenue Growth5 Y	14.93x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.51
Assets	$1.3B
Cash	$413M
Current Assets	$657M
Current Liabilities	$325M
Debt	$1.2B
Equity	$-229M
Interest Coverage	-7.7
Liabilities	$1.5B
Long Term Assets	$639M
Long Term Liabilities	$1.2B
Net Cash	$-666M
Net Cash By Market Cap	$-25.97
Tangible Book Value	$-454M
Tangible Book Value Per Share	$-4.63
WACC	5.79

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.02
Inventory Turnover	16.98
Net Working Capital	$-9M
Quick ratio	1.65
Working Capital	$332M
Working Capital Turnover	$1.81

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-6.6%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-58.64%
1Y total return	-21.84%
200-day SMA	27.69
3Y total return	-44.68%
50-day SMA	22.83
50-day SMA vs 200-day SMA	50under200
5Y total return	-77.19%
All Time High	179.6
All Time High Change	-85.46%
All Time High Date	2020-12-24
All Time Low	18.29
All Time Low Change	42.81%
All Time Low Date	2026-03-24
ATR	1.12
Beta	0.39
Beta1y	1.55
Beta2y	1.26
Ch YTD	13.57
High	26.67
High52	42.37
High52 Date	2025-07-09
High52ch	-38.35%
Low	25.93
Low52	18.29
Low52 Date	2026-03-24
Low52ch	42.81%
Ma50ch	14.42%
Premarket Change Percent	-0.27
Premarket Price	$26.06
Premarket Volume	3,877
Price vs 200-day SMA	-5.67%
RSI	67.54
RSI Monthly	40.87
RSI Weekly	50.54
Sharpe ratio	0x
Sortino ratio	0.07
Total Return	-6.6%
Tr YTD	13.57
Tr1m	12.83%
Tr1w	5.45%
Tr3m	5.75%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	20
Analyst Count Top	9
Analyst Price Target Top	$66.78
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.48
Earnings Revenue Estimate	158,979,368x
Earnings Revenue Estimate Growth	14.13x
Operating Income	$-531M
Operating margin	-79.25
Price target	$58.8
Price Target Change	$125
Price Target Change Top	$156

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	94,629,061%
Float Percent	96.37%
Shares Insiders	3.59%
Shares Institutions	95.26%
Shares Out	98,189,224
Shares Qo Q	0.7%
Shares Yo Y	6.6%
Short Float	12.77%
Short Ratio	5.76
Short Shares	12.31

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-646M
Average Volume	1,753,580.2x
Bv Per Share	-2.41
CAPEX	$-6M
Ch10y	-58.64
Ch1m	12.83
Ch1w	5.45
Ch1y	-21.84
Ch3m	5.75
Ch3y	-44.68
Ch5y	-77.19
Ch6m	-14.72
Change	-0.04%
Change From Open	0.27
Close	26.13
Days Gap	-0.31
Depreciation Amortization	34,000,000
Dollar Volume	40,670,328.8
Earnings Date	2026-05-05
Earnings Time	amc
EBIT	$-531M
EBITDA	$-497M
EPS	$-6.11
F Score	2
FCF	$-503M
FCF EV Yield	-15.57x
FCF Per Share	$-5.12
Financing CF	478,000,000
Fiscal Year End	December
Founded	2,010
Goodwill	44,000,000
Income Tax	$4M
Investing CF	67,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-18
Ma150	27.15
Ma150ch	-3.8%
Ma20	24.75
Ma20ch	5.53%
Net CF	50,000,000
Next Earnings Date	2026-08-04
Open	26.05
Optionable	Yes
Position In Range	25.68
Post Close	26.12
Postmarket Change Percent	3.37
Postmarket Price	$27
Ppne	239,000,000
Pre Close	26.13
Price Date	2026-05-08
Relative Volume	0.89x
Revenue	670,000,000x
SBC By Revenue	21.34x
Share Based Comp	143,000,000
Tax By Revenue	0.6x
Tr6m	-14.72%
Us State	California
Volume	1,557,057
Z Score	-4.48

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RARE pay a dividend?

Capital-return profile for this ticker.

Performance

RARE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RARE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+95.3%

Float: +96.4% of shares outstanding

Insider ownership

+3.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RARE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

67.5

Neutral momentum band

Price vs 200-day MA

-5.7%

50/200-day relationship not available

Beta (5Y)

0.39

Less volatile than the market

Sharpe ratio

0.00

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RARE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RARE stock rating?

Ultragenyx Pharmaceutical Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RARE analysis?

The full report lives at /stocks/RARE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RARE?

The latest report frames RARE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RARE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.